期刊
BIOMEDICINE & PHARMACOTHERAPY
卷 144, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.biopha.2021.112298
关键词
Non-alcoholic steatohepatitis (NASH); Non-alcoholic fatty liver disease (NAFLD); Succinate-GPR91; Liver fibrosis; Hepatic stellate cells (HSCs)
资金
- National Natural Science Foundation of China [81602967, 81803784]
- China Postdoctoral Science Foundation [2016M592898XB, 2019M663921XB]
- Basic Research Program of Natural Science of Shaanxi Province [2019JQ-779, 2020CGXNG-044]
- Basic Research Plan of the Education Department of Shaanxi Province [19JC006]
- Natural Science Foundation of Shandong Province [ZR2020MH141]
- Shandong Post-Doctoral Innovation Project [202003063]
- Medical and Health Science and Technology Development Program of Shandong Province [202003070813]
- Xinjiang Tianshan Innovation Team Foundation [2020D14029]
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, which can progress to non-alcoholic steatohepatitis (NASH). The pathogenesis of NASH is complex, involving multiple factors such as metabolic disorders and inflammation. Research on the succinate-GPR91 signaling pathway provides a new direction for the treatment of NASH.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and it is a liver manifes-tation of metabolic syndrome, with a histological spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH). NASH can evolve into progressive liver fibrosis and eventually lead to liver cirrhosis. The pathological mechanism of NASH is multifactorial, involving a series of metabolic disorders and changes that trigger low-level inflammation in the liver and other organs. In the pathogenesis of NASH, the signal transduction pathway involving succinate and the succinate receptor (G-protein-coupled receptor 91, GPR91) regulates inflammatory cell activation and liver fibrosis. This review describes the mechanism of the succinate-GPR91 signalling pathway in NASH and summarizes the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据